文献速递糖尿病肥胖与代谢综合征

Avexitide治疗减重术后低血糖的随机安慰剂对照交叉试验

PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

结果显示Avexitide显著升高混合餐耐量试验血糖最低值并降低胰岛素峰值,减少低血糖事件且耐受性良好。

要点

  • Avexitide 30mg每日两次和60mg每日一次分别使混合餐耐量试验血糖最低值升高21%和26%。
  • 两种剂量分别使胰岛素峰值降低23%和21%,需救援的受试者分别减少50%和75%。
  • Avexitide减少1至3级低血糖事件率,连续血糖监测未诱导临床相关高血糖。

核心结论

  • Avexitide治疗28天耐受性良好,在多项临床和代谢参数上产生稳健一致的改善,可能成为严重减重术后低血糖的首个有前景的治疗。

主要发现

  • 与安慰剂相比,Avexitide 30mg每日两次和60mg每日一次使混合餐耐量试验血糖最低值分别升高21%(P=.001)和26%(P=.0002)。
  • 两种剂量分别使胰岛素峰值降低23%(P=.029)和21%(P=.042),需救援的受试者分别减少50%和75%。
  • 观察到1至3级低血糖事件率显著降低,分别定义为自我血糖监测<70 mg/dL、<54 mg/dL和需协助的严重事件。
  • 连续血糖监测显示低血糖减少,未诱导临床相关高血糖;Avexitide耐受性良好,不良事件未增加。

关键数值与推荐

  • 1级低血糖定义为自我血糖监测<70 mg/dL,2级为<54 mg/dL,3级为需协助的严重事件。

临床怎么用

  • 对于减重术后低血糖患者,Avexitide可能作为靶向治疗选择,需进一步研究确认长期疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Postbariatric hypoglycemia (PBH), characterized by enteroinsular axis overstimulation and hyperinsulinemic hypoglycemia, is a complication of bariatric surgery for which there is no approved therapy. OBJECTIVE: To evaluate efficacy and safety of avexitide [exendin (9-39)], a glucagon-like peptide-1 antagonist, for treatment of PBH. METHODS: A multicenter, Phase 2, randomized, placebo-controlled crossover study (PREVENT). Eighteen female patients with PBH were given placebo for 14 days followed by avexitide 30 mg twice daily and 60 mg once daily, each for 14 days in random order. The main outcome measures were glucose nadir and insulin peak during mixed-meal tolerance testing (MMTT) and hypoglycemic events captured by self-monitoring of blood glucose (SMBG), electronic diary, and blinded continuous glucose monitoring (CGM). RESULTS: Compared with placebo, avexitide 30 mg twice daily and 60 mg once daily raised the glucose nadir by 21% (P = .001) and 26% (P = .0002) and lowered the insulin peak by 23% (P = .029) and 21% (P = .042), corresponding to 50% and 75% fewer participants requiring rescue during MMTT, respectively. Significant reductions in rates of Levels 1 to 3 hypoglycemia were observed, defined, respectively, as SMBG <70 mg/dL, SMBG <54 mg/dL, and a severe event characterized by altered mental and/or physical function requiring assistance. CGM demonstrated reductions in hypoglycemia without induction of clinically relevant hyperglycemia. Avexitide was well tolerated, with no increase in adverse events. CONCLUSION: Avexitide administered for 28 days was well tolerated and resulted in robust and consistent improvements across multiple clinical and metabolic parameters, reinforcing the targeted therapeutic approach and demonstrating durability of effect. Avexitide may represent a first promising treatment for patients with severe PBH.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Craig CM, Lawler HM, Lee CJE, et al. PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia. J Clin Endocrinol Metab. 2021. PMID: 33616643. doi:10.1210/clinem/dgab103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。